SSystolic ystolic HHeart failure treatment witheart failure treatment with

the the IIff inhibitor ivabradine inhibitor ivabradine TTrialrial

Efficacy and safety of ivabradine in patients Efficacy and safety of ivabradine in patients with severe chronic systolic heart with severe chronic systolic heart

failure/left ventricular dysfunction in the failure/left ventricular dysfunction in the SHIFT trialSHIFT trial

Efficacy and safety of ivabradine in patients Efficacy and safety of ivabradine in patients with severe chronic systolic heart with severe chronic systolic heart

failure/left ventricular dysfunction in the failure/left ventricular dysfunction in the SHIFT trialSHIFT trial

www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503

 Patients with heart rate ≥70 bpm

  HR P for interaction

Primary composite endpoint

Less severe heart failure (NYHA II or III and LVEF>20%)

0.82

0.854Severe heart failure (NYHA IV and/or LVEF≤20%)

0.84

Cardiovascular deathLess severe heart failure 0.94

0.264Severe heart failure 0.78

Hospitalisation for worsening heart failure

Less severe heart failure 0.73 0.419

Severe heart failure 0.83

Efficacy of ivabradine in patients according to heart failure severity

Ivabradine can be safely used in severe heart failure, and may improve clinical outcomes, independently of disease severity

www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503

0

10

20

30

40

50

60

0 1 2 3

inci

denc

e of

pri

mar

y co

mpo

stie

endp

oint

(%)

Time (years)

Ivabradine, Less severe

Ivabradine, Severe

Placebo, Less severe

Placebo, Severe

Efficacy of ivabradine in patients according to heart failure severity

www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503